|
Synonyms: CB-6 | JS-016 | LY-CoV016 | LY3832479
Compound class:
Antibody
Comment: Etesevimab (LY3832479) is a monoclonal antibody against the surface spike protein of SARS-CoV-2. It was developed by Eli Lilly, but such is the speed of COVID-19 therapeutic development, there are no peer-reviewed articles that report its design, preclinical or early clinical data.
|
| No information available. |
Summary of Clinical Use  |
| In clinical evaluation for COVID-19, alone and in combination with bamlanivimab (LY3819253, LY-CoV555). |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04441931 | A Study of LY3832479 (LY-CoV016) in Healthy Participants | Phase 1 Interventional | Eli Lilly and Company | ||
| NCT04611789 | A Study of LY3832479 (LY-CoV016) in Healthy Participants 1 | Phase 1 Interventional | Eli Lilly and Company | ||
| NCT04427501 | A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness | Phase 2 Interventional | Eli Lilly and Company | ||
